{"ticker": {"uuid": "20e45289-12de-4a65-ba9c-144df75cb591", "symbol": "AUTL", "name": "Autolus Therapeutics Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees", "summary": "Autolus Therapeutics (NASDAQ:AUTL) has granted stock option awards and restricted stock units to 13 new employees under its 2025 Inducement Plan. These awards, totaling 25,420 American Depositary Shares and 87,530 RSUs, were issued in accordance with Nasdaq Listing Rule 5635(c)(4", "url": "https://finance.yahoo.com/healthcare/articles/autolus-therapeutics-autl-grants-inducement-103319136.html", "source_name": "Market source", "published_at": "2026-07-14T10:41:16", "published_display": "14 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZGFjTnRxWmZhei0tb2UxQkJmSUszc1JIaHhIWV9LaTNjVjFHRko4OVZDSlVSM3hkc253QmQybnBLd0tiU0RLU0NYM3lEb3loV1M1YXpWSnJwRlI5MUVydGVpR2Jubm5QQ3VmQUROVDNoRU5mOFJNLTdlZjBqdHlGVTRqd2tkbkwzSHRLU0tkdVhvSVNhLWlUQmp2d3U3LWlCV25Md3pZZHJtOFpxWllDejN3cmRod3NPTEo4?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T23:28:09+00:00", "published_display": "13 Jul 2026 23:28", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AUTL PE Ratio & Valuation, Is AUTL Overvalued", "summary": "Autolus Therapeutics PLC (AUTL) is currently considered undervalued, with its forward PS ratio of 2.20 being lower than its five-year average. The fair price for AUTL is estimated to be between $2.77 and $4.57, significantly higher than its current price of $1.58. Despite a high ", "url": "https://intellectia.ai/en/stock/AUTL/valuation", "source_name": "Intellectia AI", "published_at": "2026-07-05T01:39:13", "published_display": "05 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus awards stock grants to 13 new employees", "summary": "Autolus Therapeutics (Nasdaq: AUTL) has granted equity awards to 13 new employees under its 2025 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). These awards include options for 25,420 ADSs at an exercise price of $1.66 and 87,530 RSUs, both vesting over four ", "url": "https://www.stocktitan.net/news/AUTL/autolus-therapeutics-announces-inducement-grants-under-nasdaq-be200v41qxki.html", "source_name": "Stock Titan", "published_at": "2026-07-02T01:45:25", "published_display": "02 Jul 2026 01:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus (NASDAQ: AUTL) director awarded 47,500 options and 31,667 RSUs", "summary": "Autolus Therapeutics plc director, Cynthia M. Butitta, was granted significant equity awards, including options to purchase 47,500 American Depositary Shares (ADSs) and 31,667 restricted share units (RSUs). These awards are compensation-related, not open-market transactions, with", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-1c15521170d4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:39:26", "published_display": "01 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics plc Announces Termination of John Berriman as Director, Effective June 29, 2026", "summary": "Autolus Therapeutics Plc announced the termination of John Berriman as Director, effective June 29, 2026. The company is an early commercial-stage biopharmaceutical company focused on developing programmed T cell therapies for cancer and autoimmune diseases, with an approved comm", "url": "https://www.marketscreener.com/news/autolus-therapeutics-plc-announces-termination-of-john-berriman-as-director-effective-june-29-2026-ce7f5edadd80f226", "source_name": "www.marketscreener.com", "published_at": "2026-07-01T22:10:40", "published_display": "01 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Autolus Therapeutics plc announced inducement grants to 13 new employees as per Nasdaq Listing Rule 5635(c)(4). These grants include stock option awards for 25,420 American Depositary Shares and 87,530 restricted stock units, with a grant date of June 24, 2026. The awards are str", "url": "https://www.caledonianrecord.com/autolus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/article_7364ac70-e085-5ff4-a160-1172d89627d3.html", "source_name": "Caledonian Record", "published_at": "2026-07-01T21:41:02", "published_display": "01 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) director granted options and 31,667 RSUs", "summary": "Autolus Therapeutics director William D. Young was granted equity-based compensation awards, including options to purchase 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting monthly over twelve installments starting July 29, 2026. He also received ", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-b9b26cece6dc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:22:18", "published_display": "01 Jul 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Autolus (AUTL) granted stock options and RSUs as compensation", "summary": "Autolus Therapeutics plc director Rao Madduri Ravin received new equity awards, including 47,500 share options with a $1.61 exercise price and 31,667 restricted share units (RSUs). These awards are compensation-related, with options vesting monthly starting July 29, 2026, and RSU", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-38e5f0e3bb86.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:20:18", "published_display": "01 Jul 2026 20:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) director receives new option and RSU equity awards", "summary": "Autolus Therapeutics director Robert Iannone was granted new equity awards, including options for 47,500 American Depositary Shares (ADSs) with an exercise price of $1.6100 per share, vesting monthly from July 29, 2026, and expiring on June 29, 2036. He also received 31,667 restr", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-52477687d764.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:13:19", "published_display": "01 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) director awarded new options and RSUs", "summary": "Autolus Therapeutics plc director Ryan Richardson received new equity awards comprising 47,500 stock options with a $1.61 exercise price and 31,667 restricted share units (RSUs). These grants are considered standard equity compensation, not open-market transactions, and are inten", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-e99b9773970b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:42", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) director gains new option and RSU awards", "summary": "Autolus Therapeutics director Michael W. Bonney was granted new equity compensation, including options to purchase 47,500 American Depositary Shares at $1.61 per share and 31,667 restricted share units (RSUs). These awards are subject to time-based vesting, with options vesting m", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-1a6638ad7c78.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:19", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) director granted options and RSUs in new equity awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOT05abGdvZGhnSmM1aEYxbm4xZGhfaHlEU0ZSODQ4aVJ6Y1lsMEVHWkxZc1JPbmpzRWpfQ01keUxmaC1sb1lYUTJ1bmd3enloYnZzSm5WNWZ2aFZ6NE9mUzlSbERvMXhwM0RGeXE5aWk1LW50dTlZQXV1cy0tMzgzeUszN0RsYUhCQXhRZUlkbmNkNWRfWERTdG1KZVU4Si1FQzVKcUg0WktrODlaNkVvTS0tS3FISWxSb2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus (AUTL) director granted options and 31,667 RSUs in new award", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQdFVLZEpNLW5SMGRLeUVUZzNMc0QyeXdOdnNHdWtlVEtUdThBd1RIVVhHaE00LUh3NHdTQUx2aEx0a2ZOYUFld0pnV1JROHJzMjdYaEY5Uzh5NkluTkRVQkxLN051cEd0elVKQmh1WVdRZHJIa05WUDZTR05QQTRwWHF3NmU0WVpJQ3c0a2dYN2VaOHRNOWdLWlZKTnJFWGh6Q1k0OWlyR0UyOEt2QVZaR0hCQ2JaRnpYYUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUTL: Expanding CAR T-cell therapy demonstrates robust efficacy, safety, and broadening market reach", "summary": "Autolus Therapeutics (AUTL) is highlighted for its differentiated CAR T-cell therapy, which shows strong safety and efficacy in various settings, leading to increased adoption and revenue growth. The company is pursuing further studies for broader oncology and autoimmune applicat", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3661505:0-autl-expanding-car-t-cell-therapy-demonstrates-robust-efficacy-safety-and-broadening-market-reach/", "source_name": "TradingView", "published_at": "2026-06-30T21:09:19", "published_display": "30 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUTL - Autolus Therapeutics plc ADR Options", "summary": "This article provides a detailed financial overview of Autolus Therapeutics plc (AUTL), an ADR listed healthcare biotechnology company. It includes key financial metrics such as market cap, sales, income, EPS, and various ratios, alongside performance indicators like insider and ", "url": "https://finviz.com/stock?t=AUTL&ta=2&p=d&ty=oc&ov=list_date&e=2026-12-18", "source_name": "Finviz", "published_at": "2026-06-30T09:10:42", "published_display": "30 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (NASDAQ: AUTL) passes all resolutions at 2026 AGM", "summary": "Autolus Therapeutics plc (NASDAQ: AUTL) announced that all six ordinary resolutions presented at its 2026 Annual General Meeting (AGM) were approved by shareholders. These resolutions included the adoption of the 2025 Annual Report and Accounts, approval of the directors' remuner", "url": "https://www.stocktitan.net/sec-filings/AUTL/8-k-autolus-therapeutics-plc-reports-material-event-a10424596fe8.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:11:37", "published_display": "29 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics to Participate in Upcoming Investor Conference", "summary": "Autolus Therapeutics announced its participation in an upcoming investor conference. The company will be sharing updates and engaging with the investment community at the event. Further details about the specific conference and presentation times are anticipated to be provided.", "url": "https://www.moomoo.com/news/post/72032558/autolus-therapeutics-to-participate-in-upcoming-investor-conference", "source_name": "Moomoo", "published_at": "2026-06-29T00:40:46", "published_display": "29 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Autolus Therapeutics plc \u2013 NASDAQ:AUTL", "summary": "This article provides the \"Price to book forward\" for Autolus Therapeutics plc (NASDAQ: AUTL). It presents a financial metric within the context of the company's profile on TradingView, serving as a data point for investors researching the pharmaceutical company. The page indicat", "url": "https://www.tradingview.com/symbols/NASDAQ-AUTL/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:43", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AUTL)", "summary": "This page provides financial actuals and estimates for Autolus Therapeutics Plc Sponsored ADR (NASDAQ:AUTL), allowing users to explore reported financial data and analyst estimates. It highlights key financial statements, including income, balance sheet, and cash flow, for both a", "url": "https://www.tradingview.com/symbols/NASDAQ-AUTL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:43", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Autolus Therapeutics plc \u2013 NASDAQ:AUTL", "summary": "This article provides financial data on Autolus Therapeutics plc (NASDAQ: AUTL), specifically focusing on its enterprise value to EBIT forward. It indicates various financial metrics and stock market information available on the TradingView platform for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-AUTL/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:12:31", "published_display": "25 Jun 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Autolus Therapeutics Plc Sponsored ADR \u2013 TRADEGATE:6A3A", "summary": "This article provides a financial data point for Autolus Therapeutics Plc Sponsored ADR (TRADEGATE:6A3A), specifically its enterprise value to revenue forward. It appears to be a stub or a data-focused page from TradingView, displaying a key financial metric but without further d", "url": "https://www.tradingview.com/symbols/TRADEGATE-6A3A/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:32", "published_display": "25 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus CEO Christian Itin joins June 30 cell therapy fireside chat", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNa0ZIaFIyMm5zdDZDdEVRNU11OWpOWFk1NzZUSzVJYmUtUWRmaUpVRkRsNndEVk9xLVJNcUZuSHdhdkdVODJyY2FVWG0zQkxGVWpjdXpQaUlVN3oxUVZVZEFEYzdSLWtITkY0Y25JYXRIWGRQemEzZGNaTExWbW92WFdnUE12ampadjFScmJfVW9ObUNkb0FoWkNDM01QcW5NZTBCOHg1c1BhRUJIWnp5Rw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Autolus Therapeutics plc \u2013 NASDAQ:AUTL", "summary": "This article provides financial information for Autolus Therapeutics plc (NASDAQ:AUTL), specifically focusing on its forward price-to-sales ratio. It lists the company's market and financial data sources, but does not present specific values for the ratio or its change over time.", "url": "https://www.tradingview.com/symbols/NASDAQ-AUTL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T01:09:23", "published_display": "25 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Autolus Therapeutics Plc Sponsored ADR \u2013 TRADEGATE:6A3A", "summary": "This article provides financial data for Autolus Therapeutics Plc Sponsored ADR (6A3A) on the Tradegate Exchange, specifically focusing on its forward price-to-book ratio. The content is primarily a data page from TradingView, indicating the market status, and offers a glimpse in", "url": "https://www.tradingview.com/symbols/TRADEGATE-6A3A/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T00:09:23", "published_display": "25 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Autolus Therapeutics plc \u2013 NASDAQ:AUTL", "summary": "This article displays the \"Price to earnings forward\" for Autolus Therapeutics plc (NASDAQ: AUTL). It presents a financial metric within a data table format, indicating that the value and change data for this specific period are made by humans. The article is primarily a display ", "url": "https://www.tradingview.com/symbols/NASDAQ-AUTL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T18:39:43", "published_display": "24 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) Stock Sees Split Analyst Revisions After Early Aucatyzl Launch Signals", "summary": "Analysts have provided split revisions for Autolus Therapeutics (AUTL) stock following the early commercial launch of its product, Aucatyzl. Some analysts, like H.C. Wainwright, have raised price targets to US$10 based on strong early demand signals in the U.S. and UK. Others, su", "url": "https://uk.finance.yahoo.com/news/autolus-therapeutics-autl-stock-sees-111157102.html", "source_name": "Market source", "published_at": "2026-06-24T18:11:00", "published_display": "24 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics PLC (AUTL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Autolus Therapeutics PLC's (AUTL) dividend and stock split history, noting that no dividends have been distributed in the past 5 years and there is no data on stock splits. It also includes current market data for AUTL, showing its stock price", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-autl/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:59", "published_display": "18 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics PLC (AUTL) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the major shareholders and institutional holdings of Autolus Therapeutics PLC (AUTL), providing a breakdown of shareholder types and their proportional ownership. Key investors include BioNTech SE, Syncona Investment Management Limited, and MAK Capital One, L", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-autl/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:59", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics PLC (AUTL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Autolus Therapeutics PLC (AUTL) has an earnings forecast score of 8.73, ranking 68th in its industry, with an average analyst price target of $10.00. Analysts largely recommend a \"Buy\" for the stock, forecasting next quarter's revenue at $30.24M and EPS at -$0.23. The previous qu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-autl/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:14", "published_display": "18 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Autolus Therapeutics (AUTL) Looks Less Speculative as AUCATZYL Revenue Builds", "summary": "Autolus Therapeutics (AUTL) is moving beyond speculative status as its drug AUCATZYL (obe-cel) generates significant revenue. The company reported $26.2 million in net product revenue for AUCATZYL in Q1, up from $9.0 million year-over-year, and expects 2026 revenue to be between ", "url": "https://www.insidermonkey.com/blog/why-autolus-therapeutics-autl-looks-less-speculative-as-aucatzyl-revenue-builds-1783027/", "source_name": "Insider Monkey", "published_at": "2026-06-17T11:16:00", "published_display": "17 Jun 2026 11:16", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQS3FXaF9namloR05GMGFKRlFqa1pCZG5PLTBMSll6RTVLUlNhcTJvSmd3VmJ2Zy11REtfdmJsRVJobFU3TkNWNmREMEFVZjctazBId0JlRzk3RndtZ0lTaUlQT1J5ZHBqa2ZHaFExV3hDaVFOaUlpa0lWZVN1Mi0yMldYWm1CVm5oX0ZjZ0dNTU1CM0pDNEl6UHF0SlNCQW5nUFJIQklvcw?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Autolus Therapeutics (AUTL) Investment Story Is Evolving With A Steady Analyst Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSVZGUUx5ODF1cUw1ZFU3Zmo2UzJIWkhwazFIYVFPUVhHQmlwUkxzTm9HUWU5SDhRVHFreTk2YnRzSVNIUHVGa0drVEg2b2JfSzBHU0pkblE4NFpob0U4YmRjVkozbEt0ekpHU2g4N3V0b2IxY1VsRFdkQ2VURnZCUGNYdzJUaEppNU8xS0kyWGpVcmQwLW9zajBpRlpWd09McUFmOWoyZ2JhSUk?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOT0o1WjhNcG9LOHBoLXl5OFU2WHBWeEduZ3FiLWFuVlBzV1J1cGdPRlAxdXRyZXotMEZ3cmRiWDJPZmdKRUFnU2NqNGJqMS1MeURCRGVESTlYdUM3VF9SQnBmM1VjWkNKOXg4QU50MUk3dWRoZTBSM1ZZOFBWYXlud2xLNkpMdVNMT29OSWFmSWxmci1UblhmcG5MeTB2UkJ6OE8xVFRR?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Autolus Therapeutics (NASDAQ:AUTL) Posts Inline Q1 Results with First Positive Gross Margin, but Full-Year Guidance Slightly Below Consensus", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxQcHhwWUxlZWEtQ1hsdWEwX1dKR3FVSVNSLXBvRUFWbF9ZdkJId25tTmFuUzBOdmFHc3VZaFc3Y2poTUkzVHFpaXNPS1M0RnVtTjFXTzdoQy04YU9TSmNielgxdGVEMjNYekFFRUd4WjNFd0tvU2xjdDI5WndPZHRuX1N4ZEtLY0o5aEx1SEdQd2xvaUhnaWJXVmpudnBWU0x3Z0ROOFR0RDJDdDBZZ1picktCSkZERkFCdjh1eE5OUDZKTll5WDdpOWY5VnR3SmJMa2dFZjdzeGpxa2lCVVE4aHY2OE1LbVNTY2l4UVRVNVI1VW5CREl2SVVlbnhXcGdmc2NhcHdFbVVLbDdjMVhkMGRsUGptcGs?oc=5", "source_name": "ChartMill", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Autolus Q1 2026 earnings miss, stock drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUFItdmlpQmREN2txX1FrVlZSWExSdTR0ZXhTZzE3RDI3R0lGV1NlVjZKTDZ0VTlzRkItU0VDRkhTb1Q5TXBLWDZrRGdwZC13Ym5SLTVrRU1pdk1pdHlJRDVZdnR2TzNBZF8zYjBjbXJ3SlRGSVM5V3U4MHJneEZZNE8tZGtxTEpUYVpsRVI5SEc1S1puTmRzSzJGdDk2SWtveS1sOWxtWG5zNnBGVlJ3UHhJLWZuUldVNXcxQVA2TQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Autolus Therapeutics (AUTL) to Cut Workforce by 13% While Doubling 2026 Manufacturing Capacity", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNM0toSFYwajUtOExzY1JzSmYzNlR5TktBNm9DTHBuV3VLVF9mWG1tYnZ4NkhEZUZvOXFqY2ZxcEp1T3pFanp0Y1pnX2FLS2pDaUR3NUJsNlJ4TXBUMXVXTDd6UDJOZm9IdzlDTmtnMEIxbEV3MTFOR2p6dDZqLXZkbDRPTURTeTJGRG50LURScXBabU96VTh6ZG9uSlpfU0VodmpBNWZMSmdqSURS?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus will post quarterly results before market open on May 14", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNk83c3BSQkJHRGU5MjlZNkdkaXcwYlp1ZVZQUkQ2aXNwSU1ROW5xd285S2xPUmRVNUdIcjlOTGpLQTNjNFdLTDExbHJRcjBYUDNoZ2tORzBPZl8tODV1dnNYWDl2UGl0TU12TFZRcVNPZUl4TEFaa0NscFh2M2JoSk9IdUJSRzBkVFZ1WEZpdlh6OEhoZHV2cEo0MlU5dDVDZG52NG9NcUhxQ3RfV0tnZnlRd2NtRy1oRDl0ci1ITQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Narrative On Autolus Therapeutics (AUTL) Is Shifting After Analyst Target Resets", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNOXhfZlJhTzFfTWwzcFJWc0s1OHQybDlSYzczTFBULTVQUFY2ek5PWEMyd0N2dC1uNTNiY2NQUGxrMlhMQjdoU1ZWOVgwZlpqOWNxOTJKeEdpNG15TlZpREdvY204ZTZUX184MFNMZzUtcERkV19iRUlwX3ZLLTN0VW5tNHIzSlZJNVM4WHZLRUo3X2RjWTdFYU14d2Rqc3FGX2stNTk0SjhiXzZlbWc?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Autolus Therapeutics (AUTL) One of the Best Biotech Penny Stocks to Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTjFVSXlvcDNrU3dNY2R4czJfNGZLY25ub3dFYS1yTVJ1RnFjQXJWV1ZVUFBrWTBhN3lmU2lpOXlNVzd4cGY2SklYYnphSlBrRXU0LTdqOTBDeTRSVW5rUFJuNXlFMmRjQUEzZEEtdTlJV1dRUEQ4bXNEejFDSkFHSXkzS0JvRmxIcm5iOFd4NEkzbHNSSHd0OEFWWXJQWHRSNU9EcUx3?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus plans 13% job cuts while doubling 2026 manufacturing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdFhWLVc4NEQ5MWNPQ0x4Mk9VNUJWZVBJaTVjSzhlTHYxRlRRM29QMzVqN2dRVVVCeENHQnFVbFJkNXhYemtudmlyRmtHT2VYQnVSNnZFdU5BbUxFV0Q2QW05T3BwTHZ4alI1ejRWUlJJQnlDa2Q0Ny1oNVRqY042Q3plTFl3STlGZjE1QWhWNXV2dXVSX29ESU1CUHo1dmtIYi0tdEpWQ3BMSUNMMGNYdGtzODNXRGZPTnVn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Autolus Therapeutics (AUTL) Narrative Is Shifting With Recalibrated Targets And Fair Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQS0RUSHFteTFPRmNTX0M2Q3lYdkJOUkV3OWl1YjhPaFgzeFQ4dFdhamE5ZzB3ODZVSUpSTnNNUFpYTkl1cFppRjlxUTlMYUFCeWFsVmlteWx0bTFJOVE2TFRlVEZDVnlJTGtaS0ZFQXAxMVRzeGZFNzJEQWFvZzRHZk1VZmFaLUNmMmJTRkVoYXVyc2hIdzhqeFB2N2ktVTFPOUp0dHA3dk9idjhxVlE?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Autolus targets positive gross margin in 2026 as UK launch starts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPby1rVzI4MjJzRm9XclMxZVUxUTJXZUh0eFJVRnlBRFZHUjY2T09oMXNqQkplLW5CSHNPckpKNko1U19XSk5MS2ZwcHJfQk85TmdKY1BMcDlnWnFWeGZUdUtVd2xTOTJFYWRmc0lxZ2gtVEhxem1JNXdaRnV4czVTc05ySGxGemRmdmF5UnJlLTd4SnQ2YkJNaFRVYXBIRkpjVVFMWURpaFhLZ3NadFhBVFZiWkdBYnJ6?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "22 Autolus employees get four-year stock options on 113,650 ADS", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxObkdULTFvRjl5NmZ6Z0pqMXF5UzdXOEhtejZnOHRLQ1ltWVRuUHg0TzJGbWI4dENCaFZNZ1REQ2tlOEQ1NHFaMnVlS0ZmS204NDQ2emdlNHpFc3psU2hsU2hXVl92SmtpNWFoTDNGcVF5OWJQemlrN0UxekZ1VmhPWEJKNWJNQUl5eTh1RGd1bDV1WXp6ZnJlTmFCdncwMFhhWTBkLVNGOXk5R05zOEZ3dDdNekhHRTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQTXJuLUFfMEgwSWtHMWhTdUpBbjFkVzVySDNjek5pcHNNbUt4MEJFX29hU0tpN3h3WTFHSEQ5Z2M4U3Q0WjdrNGZVakE4YkxGeVhuM3ZQVzlmNngzMHVHZ1F5TUV2Vk1XVllCelR1RklSN0Nnc0ZJV1dxN2dvS29wTkxmS3RabVBzVzktUGtBQUpMNGh6TGkxVS1nOEFPV3FXeFBnRnBxTC1TWTFHMTMtMGFFR0t1S1owUTNYUU9MMW1yQlloMzhJMWt3U0R3RGNadnRiWTBiWlVmM3hGcGREWUdQNjZvcHZEdlHSAe8BQVVfeXFMTWZ0RGNBbDlQbmp1UWU4bTQ0WmRJajVWRzRmYmhlU3pObGdSNVAtQXpEcERfbHBiTnlzRTBQQlJ3R0pBa3AtbmFaZDJsSkZfZDk3b25vYm1fWVh1S0hpWDVIaWd3QlU5Y2dxUnBRQllfY0FyaTU2NXlET2l6SE1PYzNTUk5OeVQxYS14cnc5M2VBOW1EdXBNeWVzWUpoWTQ4UFVQa2pTc1dLOTJVTm5fRGFEYUVRZmIxaHlhQWpIZ21UNlFaczRDZGw3ZHpMUlp1SjYwc0FXaFBXdHk0dEk5c21OSnlKSDJuQk8wWm5ZTkE?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Autolus Therapeutics (AUTL) Pairing AUCATZYL Approvals With Revenue Guidance Redefine Its Long-Term Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNOG1pLWZMdzJFM0xBaFdmMUpQZ2dxaEd1Z3c0dDYzSzZKd1phV3ZkejdvWHBJaHFKYUprVE5FcW9RcGZrQ21WeHVZa0l1S1B4dzNkZnc4aUIxUVZVNWtkTldEcFNZSXJYWHBwR1oxbTEzS2FXMGlDZE5ucU0ta3RhYWh6dHR5Y0UwZ0s5Sw?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) Is Down 25.0% After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) Valuation Check After Revenue Guidance And AUCATZYL UK And EU Approvals", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNSUdrQ2l4d0J4X0ctZXpNcUx0aThjQmZnZXRFdjdtRW1aWGlsXzRmMzhkdkRzY2FpUHFHTFBaTEdYYjBhSUs1a2h1R1czLVNjRW0tblp2TXRxcGljUDluSktrVDQxZE5LTERJb0lfLVRSWDFma3UwS1FkbjRjc2ptbV82WnMwdW4xcGRWV084VmQ?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOQkZteDlFVUJwdXVKc0d4OU9Xd2ZuemtpMEJ2d3BZR2MzZnlkX0RFQ2d4T2lObnlHMWgxTVRCMVpnU2Z4ZXdhaF9tMlExUDhjRE9VZ3BaR1g4c1JJRDJXZEl6SnBxRkZld25WVkFBYnhYYkxEcEhFYV9odmY3NXpodC1OUi1GQXM?oc=5", "source_name": "Market source", "published_at": "2025-12-27T08:00:00+00:00", "published_display": "27 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Fresh Look at Autolus Therapeutics (AUTL) Valuation Following Earnings, Obe-cel Expansion, and Anticipated ASH Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-15T08:00:00+00:00", "published_display": "15 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus: Good Product, But Tricky Market Dynamics (Rating Downgrade) (NASDAQ:AUTL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNQlpYck5ZYnhsa2pXdlZBcVYtRzJJY21SakMzU19ocmd2S21Qa2tOcUdTeHFLN0VmdHJVZnhfMzJnQXp2bEt3d1Z0eGdzVmhQWExuM3RPczBaU3hGNXV0YXBjNmVfb1FwRkxJWWY1YllSeXZsc0hfNGpFenIwOGZWeTlNQ0gtM3pJWEcxMHJtZGJBbVJtd1RtR18ySFdRZmdqSmw4RGdfWkY?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-01T07:00:00+00:00", "published_display": "01 Nov 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUTOLUS THERAPEUTICS PLC (AUTL) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9sTmhKVU5sUDJseHdDT0t2VnIydjRIaG44YURQNmNocTltemZBcG5IMXNfMjZJT29fLWtHbWx6Yy01SGh3c0dnaEdySmpHZHcwNnVV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:55:43+00:00", "published_display": "25 Apr 2025 02:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees", "summary": "Autolus Therapeutics (NASDAQ:AUTL) has granted stock option awards and restricted stock units to 13 new employees under its 2025 Inducement Plan. These awards, totaling 25,420 American Depositary Shares and 87,530 RSUs, were issued in accordance with Nasdaq Listing Rule 5635(c)(4", "url": "https://finance.yahoo.com/healthcare/articles/autolus-therapeutics-autl-grants-inducement-103319136.html", "source_name": "Market source", "published_at": "2026-07-14T10:41:16", "published_display": "14 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZGFjTnRxWmZhei0tb2UxQkJmSUszc1JIaHhIWV9LaTNjVjFHRko4OVZDSlVSM3hkc253QmQybnBLd0tiU0RLU0NYM3lEb3loV1M1YXpWSnJwRlI5MUVydGVpR2Jubm5QQ3VmQUROVDNoRU5mOFJNLTdlZjBqdHlGVTRqd2tkbkwzSHRLU0tkdVhvSVNhLWlUQmp2d3U3LWlCV25Md3pZZHJtOFpxWllDejN3cmRod3NPTEo4?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T23:28:09+00:00", "published_display": "13 Jul 2026 23:28", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUTL PE Ratio & Valuation, Is AUTL Overvalued", "summary": "Autolus Therapeutics PLC (AUTL) is currently considered undervalued, with its forward PS ratio of 2.20 being lower than its five-year average. The fair price for AUTL is estimated to be between $2.77 and $4.57, significantly higher than its current price of $1.58. Despite a high ", "url": "https://intellectia.ai/en/stock/AUTL/valuation", "source_name": "Intellectia AI", "published_at": "2026-07-05T01:39:13", "published_display": "05 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus awards stock grants to 13 new employees", "summary": "Autolus Therapeutics (Nasdaq: AUTL) has granted equity awards to 13 new employees under its 2025 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). These awards include options for 25,420 ADSs at an exercise price of $1.66 and 87,530 RSUs, both vesting over four ", "url": "https://www.stocktitan.net/news/AUTL/autolus-therapeutics-announces-inducement-grants-under-nasdaq-be200v41qxki.html", "source_name": "Stock Titan", "published_at": "2026-07-02T01:45:25", "published_display": "02 Jul 2026 01:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus (NASDAQ: AUTL) director awarded 47,500 options and 31,667 RSUs", "summary": "Autolus Therapeutics plc director, Cynthia M. Butitta, was granted significant equity awards, including options to purchase 47,500 American Depositary Shares (ADSs) and 31,667 restricted share units (RSUs). These awards are compensation-related, not open-market transactions, with", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-1c15521170d4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:39:26", "published_display": "01 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics plc Announces Termination of John Berriman as Director, Effective June 29, 2026", "summary": "Autolus Therapeutics Plc announced the termination of John Berriman as Director, effective June 29, 2026. The company is an early commercial-stage biopharmaceutical company focused on developing programmed T cell therapies for cancer and autoimmune diseases, with an approved comm", "url": "https://www.marketscreener.com/news/autolus-therapeutics-plc-announces-termination-of-john-berriman-as-director-effective-june-29-2026-ce7f5edadd80f226", "source_name": "www.marketscreener.com", "published_at": "2026-07-01T22:10:40", "published_display": "01 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Autolus Therapeutics plc announced inducement grants to 13 new employees as per Nasdaq Listing Rule 5635(c)(4). These grants include stock option awards for 25,420 American Depositary Shares and 87,530 restricted stock units, with a grant date of June 24, 2026. The awards are str", "url": "https://www.caledonianrecord.com/autolus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/article_7364ac70-e085-5ff4-a160-1172d89627d3.html", "source_name": "Caledonian Record", "published_at": "2026-07-01T21:41:02", "published_display": "01 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) director granted options and 31,667 RSUs", "summary": "Autolus Therapeutics director William D. Young was granted equity-based compensation awards, including options to purchase 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting monthly over twelve installments starting July 29, 2026. He also received ", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-b9b26cece6dc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:22:18", "published_display": "01 Jul 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Autolus (AUTL) granted stock options and RSUs as compensation", "summary": "Autolus Therapeutics plc director Rao Madduri Ravin received new equity awards, including 47,500 share options with a $1.61 exercise price and 31,667 restricted share units (RSUs). These awards are compensation-related, with options vesting monthly starting July 29, 2026, and RSU", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-38e5f0e3bb86.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:20:18", "published_display": "01 Jul 2026 20:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) director receives new option and RSU equity awards", "summary": "Autolus Therapeutics director Robert Iannone was granted new equity awards, including options for 47,500 American Depositary Shares (ADSs) with an exercise price of $1.6100 per share, vesting monthly from July 29, 2026, and expiring on June 29, 2036. He also received 31,667 restr", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-52477687d764.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:13:19", "published_display": "01 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) director awarded new options and RSUs", "summary": "Autolus Therapeutics plc director Ryan Richardson received new equity awards comprising 47,500 stock options with a $1.61 exercise price and 31,667 restricted share units (RSUs). These grants are considered standard equity compensation, not open-market transactions, and are inten", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-e99b9773970b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:42", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) director gains new option and RSU awards", "summary": "Autolus Therapeutics director Michael W. Bonney was granted new equity compensation, including options to purchase 47,500 American Depositary Shares at $1.61 per share and 31,667 restricted share units (RSUs). These awards are subject to time-based vesting, with options vesting m", "url": "https://www.stocktitan.net/sec-filings/AUTL/form-4-autolus-therapeutics-plc-insider-trading-activity-1a6638ad7c78.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:19", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) director granted options and RSUs in new equity awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOT05abGdvZGhnSmM1aEYxbm4xZGhfaHlEU0ZSODQ4aVJ6Y1lsMEVHWkxZc1JPbmpzRWpfQ01keUxmaC1sb1lYUTJ1bmd3enloYnZzSm5WNWZ2aFZ6NE9mUzlSbERvMXhwM0RGeXE5aWk1LW50dTlZQXV1cy0tMzgzeUszN0RsYUhCQXhRZUlkbmNkNWRfWERTdG1KZVU4Si1FQzVKcUg0WktrODlaNkVvTS0tS3FISWxSb2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus (AUTL) director granted options and 31,667 RSUs in new award", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQdFVLZEpNLW5SMGRLeUVUZzNMc0QyeXdOdnNHdWtlVEtUdThBd1RIVVhHaE00LUh3NHdTQUx2aEx0a2ZOYUFld0pnV1JROHJzMjdYaEY5Uzh5NkluTkRVQkxLN051cEd0elVKQmh1WVdRZHJIa05WUDZTR05QQTRwWHF3NmU0WVpJQ3c0a2dYN2VaOHRNOWdLWlZKTnJFWGh6Q1k0OWlyR0UyOEt2QVZaR0hCQ2JaRnpYYUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUTL: Expanding CAR T-cell therapy demonstrates robust efficacy, safety, and broadening market reach", "summary": "Autolus Therapeutics (AUTL) is highlighted for its differentiated CAR T-cell therapy, which shows strong safety and efficacy in various settings, leading to increased adoption and revenue growth. The company is pursuing further studies for broader oncology and autoimmune applicat", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3661505:0-autl-expanding-car-t-cell-therapy-demonstrates-robust-efficacy-safety-and-broadening-market-reach/", "source_name": "TradingView", "published_at": "2026-06-30T21:09:19", "published_display": "30 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUTL - Autolus Therapeutics plc ADR Options", "summary": "This article provides a detailed financial overview of Autolus Therapeutics plc (AUTL), an ADR listed healthcare biotechnology company. It includes key financial metrics such as market cap, sales, income, EPS, and various ratios, alongside performance indicators like insider and ", "url": "https://finviz.com/stock?t=AUTL&ta=2&p=d&ty=oc&ov=list_date&e=2026-12-18", "source_name": "Finviz", "published_at": "2026-06-30T09:10:42", "published_display": "30 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (NASDAQ: AUTL) passes all resolutions at 2026 AGM", "summary": "Autolus Therapeutics plc (NASDAQ: AUTL) announced that all six ordinary resolutions presented at its 2026 Annual General Meeting (AGM) were approved by shareholders. These resolutions included the adoption of the 2025 Annual Report and Accounts, approval of the directors' remuner", "url": "https://www.stocktitan.net/sec-filings/AUTL/8-k-autolus-therapeutics-plc-reports-material-event-a10424596fe8.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:11:37", "published_display": "29 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics to Participate in Upcoming Investor Conference", "summary": "Autolus Therapeutics announced its participation in an upcoming investor conference. The company will be sharing updates and engaging with the investment community at the event. Further details about the specific conference and presentation times are anticipated to be provided.", "url": "https://www.moomoo.com/news/post/72032558/autolus-therapeutics-to-participate-in-upcoming-investor-conference", "source_name": "Moomoo", "published_at": "2026-06-29T00:40:46", "published_display": "29 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Autolus Therapeutics plc \u2013 NASDAQ:AUTL", "summary": "This article provides the \"Price to book forward\" for Autolus Therapeutics plc (NASDAQ: AUTL). It presents a financial metric within the context of the company's profile on TradingView, serving as a data point for investors researching the pharmaceutical company. The page indicat", "url": "https://www.tradingview.com/symbols/NASDAQ-AUTL/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:43", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AUTL)", "summary": "This page provides financial actuals and estimates for Autolus Therapeutics Plc Sponsored ADR (NASDAQ:AUTL), allowing users to explore reported financial data and analyst estimates. It highlights key financial statements, including income, balance sheet, and cash flow, for both a", "url": "https://www.tradingview.com/symbols/NASDAQ-AUTL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:43", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Autolus Therapeutics plc \u2013 NASDAQ:AUTL", "summary": "This article provides financial data on Autolus Therapeutics plc (NASDAQ: AUTL), specifically focusing on its enterprise value to EBIT forward. It indicates various financial metrics and stock market information available on the TradingView platform for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-AUTL/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:12:31", "published_display": "25 Jun 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Autolus Therapeutics Plc Sponsored ADR \u2013 TRADEGATE:6A3A", "summary": "This article provides a financial data point for Autolus Therapeutics Plc Sponsored ADR (TRADEGATE:6A3A), specifically its enterprise value to revenue forward. It appears to be a stub or a data-focused page from TradingView, displaying a key financial metric but without further d", "url": "https://www.tradingview.com/symbols/TRADEGATE-6A3A/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:32", "published_display": "25 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus CEO Christian Itin joins June 30 cell therapy fireside chat", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNa0ZIaFIyMm5zdDZDdEVRNU11OWpOWFk1NzZUSzVJYmUtUWRmaUpVRkRsNndEVk9xLVJNcUZuSHdhdkdVODJyY2FVWG0zQkxGVWpjdXpQaUlVN3oxUVZVZEFEYzdSLWtITkY0Y25JYXRIWGRQemEzZGNaTExWbW92WFdnUE12ampadjFScmJfVW9ObUNkb0FoWkNDM01QcW5NZTBCOHg1c1BhRUJIWnp5Rw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Autolus Therapeutics plc \u2013 NASDAQ:AUTL", "summary": "This article provides financial information for Autolus Therapeutics plc (NASDAQ:AUTL), specifically focusing on its forward price-to-sales ratio. It lists the company's market and financial data sources, but does not present specific values for the ratio or its change over time.", "url": "https://www.tradingview.com/symbols/NASDAQ-AUTL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T01:09:23", "published_display": "25 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Autolus Therapeutics Plc Sponsored ADR \u2013 TRADEGATE:6A3A", "summary": "This article provides financial data for Autolus Therapeutics Plc Sponsored ADR (6A3A) on the Tradegate Exchange, specifically focusing on its forward price-to-book ratio. The content is primarily a data page from TradingView, indicating the market status, and offers a glimpse in", "url": "https://www.tradingview.com/symbols/TRADEGATE-6A3A/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T00:09:23", "published_display": "25 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Autolus Therapeutics plc \u2013 NASDAQ:AUTL", "summary": "This article displays the \"Price to earnings forward\" for Autolus Therapeutics plc (NASDAQ: AUTL). It presents a financial metric within a data table format, indicating that the value and change data for this specific period are made by humans. The article is primarily a display ", "url": "https://www.tradingview.com/symbols/NASDAQ-AUTL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T18:39:43", "published_display": "24 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) Stock Sees Split Analyst Revisions After Early Aucatyzl Launch Signals", "summary": "Analysts have provided split revisions for Autolus Therapeutics (AUTL) stock following the early commercial launch of its product, Aucatyzl. Some analysts, like H.C. Wainwright, have raised price targets to US$10 based on strong early demand signals in the U.S. and UK. Others, su", "url": "https://uk.finance.yahoo.com/news/autolus-therapeutics-autl-stock-sees-111157102.html", "source_name": "Market source", "published_at": "2026-06-24T18:11:00", "published_display": "24 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics PLC (AUTL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Autolus Therapeutics PLC's (AUTL) dividend and stock split history, noting that no dividends have been distributed in the past 5 years and there is no data on stock splits. It also includes current market data for AUTL, showing its stock price", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-autl/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:59", "published_display": "18 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics PLC (AUTL) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the major shareholders and institutional holdings of Autolus Therapeutics PLC (AUTL), providing a breakdown of shareholder types and their proportional ownership. Key investors include BioNTech SE, Syncona Investment Management Limited, and MAK Capital One, L", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-autl/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:59", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics PLC (AUTL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Autolus Therapeutics PLC (AUTL) has an earnings forecast score of 8.73, ranking 68th in its industry, with an average analyst price target of $10.00. Analysts largely recommend a \"Buy\" for the stock, forecasting next quarter's revenue at $30.24M and EPS at -$0.23. The previous qu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-autl/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:14", "published_display": "18 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Autolus Therapeutics (AUTL) Looks Less Speculative as AUCATZYL Revenue Builds", "summary": "Autolus Therapeutics (AUTL) is moving beyond speculative status as its drug AUCATZYL (obe-cel) generates significant revenue. The company reported $26.2 million in net product revenue for AUCATZYL in Q1, up from $9.0 million year-over-year, and expects 2026 revenue to be between ", "url": "https://www.insidermonkey.com/blog/why-autolus-therapeutics-autl-looks-less-speculative-as-aucatzyl-revenue-builds-1783027/", "source_name": "Insider Monkey", "published_at": "2026-06-17T11:16:00", "published_display": "17 Jun 2026 11:16", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQS3FXaF9namloR05GMGFKRlFqa1pCZG5PLTBMSll6RTVLUlNhcTJvSmd3VmJ2Zy11REtfdmJsRVJobFU3TkNWNmREMEFVZjctazBId0JlRzk3RndtZ0lTaUlQT1J5ZHBqa2ZHaFExV3hDaVFOaUlpa0lWZVN1Mi0yMldYWm1CVm5oX0ZjZ0dNTU1CM0pDNEl6UHF0SlNCQW5nUFJIQklvcw?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Autolus Therapeutics (AUTL) Investment Story Is Evolving With A Steady Analyst Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSVZGUUx5ODF1cUw1ZFU3Zmo2UzJIWkhwazFIYVFPUVhHQmlwUkxzTm9HUWU5SDhRVHFreTk2YnRzSVNIUHVGa0drVEg2b2JfSzBHU0pkblE4NFpob0U4YmRjVkozbEt0ekpHU2g4N3V0b2IxY1VsRFdkQ2VURnZCUGNYdzJUaEppNU8xS0kyWGpVcmQwLW9zajBpRlpWd09McUFmOWoyZ2JhSUk?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOT0o1WjhNcG9LOHBoLXl5OFU2WHBWeEduZ3FiLWFuVlBzV1J1cGdPRlAxdXRyZXotMEZ3cmRiWDJPZmdKRUFnU2NqNGJqMS1MeURCRGVESTlYdUM3VF9SQnBmM1VjWkNKOXg4QU50MUk3dWRoZTBSM1ZZOFBWYXlud2xLNkpMdVNMT29OSWFmSWxmci1UblhmcG5MeTB2UkJ6OE8xVFRR?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (NASDAQ:AUTL) Posts Inline Q1 Results with First Positive Gross Margin, but Full-Year Guidance Slightly Below Consensus", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxQcHhwWUxlZWEtQ1hsdWEwX1dKR3FVSVNSLXBvRUFWbF9ZdkJId25tTmFuUzBOdmFHc3VZaFc3Y2poTUkzVHFpaXNPS1M0RnVtTjFXTzdoQy04YU9TSmNielgxdGVEMjNYekFFRUd4WjNFd0tvU2xjdDI5WndPZHRuX1N4ZEtLY0o5aEx1SEdQd2xvaUhnaWJXVmpudnBWU0x3Z0ROOFR0RDJDdDBZZ1picktCSkZERkFCdjh1eE5OUDZKTll5WDdpOWY5VnR3SmJMa2dFZjdzeGpxa2lCVVE4aHY2OE1LbVNTY2l4UVRVNVI1VW5CREl2SVVlbnhXcGdmc2NhcHdFbVVLbDdjMVhkMGRsUGptcGs?oc=5", "source_name": "ChartMill", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Autolus Q1 2026 earnings miss, stock drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUFItdmlpQmREN2txX1FrVlZSWExSdTR0ZXhTZzE3RDI3R0lGV1NlVjZKTDZ0VTlzRkItU0VDRkhTb1Q5TXBLWDZrRGdwZC13Ym5SLTVrRU1pdk1pdHlJRDVZdnR2TzNBZF8zYjBjbXJ3SlRGSVM5V3U4MHJneEZZNE8tZGtxTEpUYVpsRVI5SEc1S1puTmRzSzJGdDk2SWtveS1sOWxtWG5zNnBGVlJ3UHhJLWZuUldVNXcxQVA2TQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) to Cut Workforce by 13% While Doubling 2026 Manufacturing Capacity", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNM0toSFYwajUtOExzY1JzSmYzNlR5TktBNm9DTHBuV3VLVF9mWG1tYnZ4NkhEZUZvOXFqY2ZxcEp1T3pFanp0Y1pnX2FLS2pDaUR3NUJsNlJ4TXBUMXVXTDd6UDJOZm9IdzlDTmtnMEIxbEV3MTFOR2p6dDZqLXZkbDRPTURTeTJGRG50LURScXBabU96VTh6ZG9uSlpfU0VodmpBNWZMSmdqSURS?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus will post quarterly results before market open on May 14", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNk83c3BSQkJHRGU5MjlZNkdkaXcwYlp1ZVZQUkQ2aXNwSU1ROW5xd285S2xPUmRVNUdIcjlOTGpLQTNjNFdLTDExbHJRcjBYUDNoZ2tORzBPZl8tODV1dnNYWDl2UGl0TU12TFZRcVNPZUl4TEFaa0NscFh2M2JoSk9IdUJSRzBkVFZ1WEZpdlh6OEhoZHV2cEo0MlU5dDVDZG52NG9NcUhxQ3RfV0tnZnlRd2NtRy1oRDl0ci1ITQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Narrative On Autolus Therapeutics (AUTL) Is Shifting After Analyst Target Resets", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNOXhfZlJhTzFfTWwzcFJWc0s1OHQybDlSYzczTFBULTVQUFY2ek5PWEMyd0N2dC1uNTNiY2NQUGxrMlhMQjdoU1ZWOVgwZlpqOWNxOTJKeEdpNG15TlZpREdvY204ZTZUX184MFNMZzUtcERkV19iRUlwX3ZLLTN0VW5tNHIzSlZJNVM4WHZLRUo3X2RjWTdFYU14d2Rqc3FGX2stNTk0SjhiXzZlbWc?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Autolus Therapeutics (AUTL) One of the Best Biotech Penny Stocks to Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTjFVSXlvcDNrU3dNY2R4czJfNGZLY25ub3dFYS1yTVJ1RnFjQXJWV1ZVUFBrWTBhN3lmU2lpOXlNVzd4cGY2SklYYnphSlBrRXU0LTdqOTBDeTRSVW5rUFJuNXlFMmRjQUEzZEEtdTlJV1dRUEQ4bXNEejFDSkFHSXkzS0JvRmxIcm5iOFd4NEkzbHNSSHd0OEFWWXJQWHRSNU9EcUx3?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus plans 13% job cuts while doubling 2026 manufacturing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdFhWLVc4NEQ5MWNPQ0x4Mk9VNUJWZVBJaTVjSzhlTHYxRlRRM29QMzVqN2dRVVVCeENHQnFVbFJkNXhYemtudmlyRmtHT2VYQnVSNnZFdU5BbUxFV0Q2QW05T3BwTHZ4alI1ejRWUlJJQnlDa2Q0Ny1oNVRqY042Q3plTFl3STlGZjE1QWhWNXV2dXVSX29ESU1CUHo1dmtIYi0tdEpWQ3BMSUNMMGNYdGtzODNXRGZPTnVn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Autolus Therapeutics (AUTL) Narrative Is Shifting With Recalibrated Targets And Fair Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQS0RUSHFteTFPRmNTX0M2Q3lYdkJOUkV3OWl1YjhPaFgzeFQ4dFdhamE5ZzB3ODZVSUpSTnNNUFpYTkl1cFppRjlxUTlMYUFCeWFsVmlteWx0bTFJOVE2TFRlVEZDVnlJTGtaS0ZFQXAxMVRzeGZFNzJEQWFvZzRHZk1VZmFaLUNmMmJTRkVoYXVyc2hIdzhqeFB2N2ktVTFPOUp0dHA3dk9idjhxVlE?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus targets positive gross margin in 2026 as UK launch starts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPby1rVzI4MjJzRm9XclMxZVUxUTJXZUh0eFJVRnlBRFZHUjY2T09oMXNqQkplLW5CSHNPckpKNko1U19XSk5MS2ZwcHJfQk85TmdKY1BMcDlnWnFWeGZUdUtVd2xTOTJFYWRmc0lxZ2gtVEhxem1JNXdaRnV4czVTc05ySGxGemRmdmF5UnJlLTd4SnQ2YkJNaFRVYXBIRkpjVVFMWURpaFhLZ3NadFhBVFZiWkdBYnJ6?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "22 Autolus employees get four-year stock options on 113,650 ADS", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxObkdULTFvRjl5NmZ6Z0pqMXF5UzdXOEhtejZnOHRLQ1ltWVRuUHg0TzJGbWI4dENCaFZNZ1REQ2tlOEQ1NHFaMnVlS0ZmS204NDQ2emdlNHpFc3psU2hsU2hXVl92SmtpNWFoTDNGcVF5OWJQemlrN0UxekZ1VmhPWEJKNWJNQUl5eTh1RGd1bDV1WXp6ZnJlTmFCdncwMFhhWTBkLVNGOXk5R05zOEZ3dDdNekhHRTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Autolus Therapeutics (AUTL) Pairing AUCATZYL Approvals With Revenue Guidance Redefine Its Long-Term Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNOG1pLWZMdzJFM0xBaFdmMUpQZ2dxaEd1Z3c0dDYzSzZKd1phV3ZkejdvWHBJaHFKYUprVE5FcW9RcGZrQ21WeHVZa0l1S1B4dzNkZnc4aUIxUVZVNWtkTldEcFNZSXJYWHBwR1oxbTEzS2FXMGlDZE5ucU0ta3RhYWh6dHR5Y0UwZ0s5Sw?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) Is Down 25.0% After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNRzBMMWN4UVIxNXY1MzdxeHhJRVc3ak9vVXVZV3pEY040TTliOWtReDlIM3BkSU5TaWFBamp2NzRGUHBuVG85cmxHQWxLNjJ3ZlZKZlBKdWxaNFBXem9QM2dnMF9aa1F0TW1mb1dZdkoxcmVHcEplZm1oODlpN3hUX08wYS1pX3ZBR2tpZkJaVWdVdnN4X3VOdEhHOElqOUJFSC0zUF9RVFJSVlBjYVpLRFFLZEdDdWRrZmdRMmkzTzNmVWF3NXVfSVotVk1xNGdOSkhlOWw3cjM0QXNldGJDU3dsd1JMeGdWMEHSAe8BQVVfeXFMUFJKTW5DWUltZUUySHRrZHZyUm1oOWdIOHFSbnB0LTliY29SVkdSUG9qWTdQaGpQSkxCbVpTYUJkQk50b2Jwc3I4ZW1TdjBITUwtTUotcGoyT2NHT0JMc0JXSzBGZ2ZIWWpQV3hCakE0M2xQVHNXTUg4TWpEOVZhOThwRHN2T29aMVotMVBnOEs5WmctdlhwMlpGWnBUNlc3YUNVY2h2N1ROLVZHWHZTSEhEc2ZaRmhlZ0FpWHVVSEprdGRpRTBKMkF4eWc4OW9SUkE3WjhsOVFTQ0pnQlpnSXNPaDBSZGJTNWhVcFJHdjg?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus Therapeutics (AUTL) Valuation Check After Revenue Guidance And AUCATZYL UK And EU Approvals", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNSUdrQ2l4d0J4X0ctZXpNcUx0aThjQmZnZXRFdjdtRW1aWGlsXzRmMzhkdkRzY2FpUHFHTFBaTEdYYjBhSUs1a2h1R1czLVNjRW0tblp2TXRxcGljUDluSktrVDQxZE5LTERJb0lfLVRSWDFma3UwS1FkbjRjc2ptbV82WnMwdW4xcGRWV084VmQ?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOQkZteDlFVUJwdXVKc0d4OU9Xd2ZuemtpMEJ2d3BZR2MzZnlkX0RFQ2d4T2lObnlHMWgxTVRCMVpnU2Z4ZXdhaF9tMlExUDhjRE9VZ3BaR1g4c1JJRDJXZEl6SnBxRkZld25WVkFBYnhYYkxEcEhFYV9odmY3NXpodC1OUi1GQXM?oc=5", "source_name": "Market source", "published_at": "2025-12-27T08:00:00+00:00", "published_display": "27 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Fresh Look at Autolus Therapeutics (AUTL) Valuation Following Earnings, Obe-cel Expansion, and Anticipated ASH Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-15T08:00:00+00:00", "published_display": "15 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autolus: Good Product, But Tricky Market Dynamics (Rating Downgrade) (NASDAQ:AUTL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNQlpYck5ZYnhsa2pXdlZBcVYtRzJJY21SakMzU19ocmd2S21Qa2tOcUdTeHFLN0VmdHJVZnhfMzJnQXp2bEt3d1Z0eGdzVmhQWExuM3RPczBaU3hGNXV0YXBjNmVfb1FwRkxJWWY1YllSeXZsc0hfNGpFenIwOGZWeTlNQ0gtM3pJWEcxMHJtZGJBbVJtd1RtR18ySFdRZmdqSmw4RGdfWkY?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-01T07:00:00+00:00", "published_display": "01 Nov 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AUTOLUS THERAPEUTICS PLC (AUTL) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9sTmhKVU5sUDJseHdDT0t2VnIydjRIaG44YURQNmNocTltemZBcG5IMXNfMjZJT29fLWtHbWx6Yy01SGh3c0dnaEdySmpHZHcwNnVV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:55:43+00:00", "published_display": "25 Apr 2025 02:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 61, "sentiment_summary": {"positive": 15, "negative": 6, "neutral": 40, "score": 53, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 11.0, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 3.1, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 1.61, "latest_week": "2026-07-10", "one_week_move": 1.9, "four_week_move": 3.2, "twelve_week_move": 0.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.423705, "market_dynamics_buy_signal": false, "relative_strength": -14.314512, "fair_value_gap": -44.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 50.8371, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.9% over one week, +3.2% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 17}, {"label": "Stock Titan", "count": 16}, {"label": "TradingView", "count": 9}, {"label": "simplywall.st", "count": 5}, {"label": "TradingKey", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Intellectia AI", "count": 1}, {"label": "www.marketscreener.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 22}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+1.9% over one week, +3.2% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees"}], "updated_at": "2026-07-16T11:51:04.247908+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}